




EL EXOSOME™

**Immuno-exosome extracted from
human cord blood immune precursor cells**



Formula 1 • Formula 2

Formula 1: Progenitor Cell
Immune Exosome + Hyaluronic Acid
Lyophilized 20mg

Formula 2: PDRN + Niacinamide 5ml

Patent 10-2284304
Procurement of progenitor cells and
method for producing exosome therefrom.






Formula 1

Immuno-exosome


Benefits of Immuno-exosome

The immuno-exosome secrete from Dynamic Linker Cell (DLC) can fundamentally solve skin-related problems such as wrinkles, elasticity, regeneration, brightening, and sensitivity.




01 Antioxidant

Antioxidants protect the skin and other cells by fighting free radicals that can cause damage and signs of aging.



02 Cell Proliferation

Promotes cell differentiation to restore collagen and elastin. Improve skin elasticity and reduces wrinkle.



03 Cell Migration

Promotes cell migration to heal wounds and repair damaged tissue quickly & efficiently.




04 Anti-inflammatory

Inhibits inflammatory cytokines such as IL-6, TNF-α ELISA assay to promote cell differentiation and elasticity.

First detection of immune progenitor cells

Inflammatory cytokines secreted by the skin immune cells cause the skin to wrinkle and cause degradation to restore collagen and elastin.

- Anti-Inflammation
- Anti-Wrinkle
- Rejuvenation
- Promote Elasticity




[Immune Primary Cell Exosome]

We found a family of immune progenitor cells in the study of neonatal umbilical cord blood and mass-producing the high-purified immuno-exosome from the DLC.

We're studying whether the immuno-exosome secrete from DLC cells act specifically on T cells, dendritic cells, and macrophages of the immune system to reduce inflammatory cytokines and promote the skin cell differentiation and migration.


Immuno-exosome purification process



1. Produced by culturing TIMEBIO's Progenitor Cell originated from human umbilical cord blood
2. Removing proteins efficiently like IL-8z, EGF, PDGF, TGFb, TNFa, MCP-1z, etc.
3. The only sterilization technology in Korea applying highly purified Immuno-exosome
4. Ensuring the safety of Immuno-exosome raw materials with strict quality control
5. ATO Standard's core raw material

Principal ingredients (Proteins)

Important for Skin Regeneration Contained in Bio Exosome



Proteins

PRX-6 Enzyme

One of the antioxidant enzymes that suppress reactive oxygen species (ROS) in the human body.

Collagen Type I

A key Collagen that forms the structure of various tissues.

Collagen Type VI, Alpha 1,2,3

Major collagen for skin fibroblast formation.

Retinol-binding Protein4 (RBP4)


Essential protein that binds to retinol and delivers to skin cell.

We discovered and named


DLC (Dynamic Linker Cell)

of immune progenitor on cord blood cell isolation.

Immuno-exosome is a pure exosome manufactured through purification and sterilization of DLC. It is a cell with completely differentiated biological characteristics from Mesenchymal Stem Cell (MSC) derived exosomes.



VS



DLC Exosome



- Small size and compact.
- High purity.

MSC Exosome

- Large size & sparse.
- Contains other foreign substances such as cytokines.

Cell Migration Study – 1







Comparison of MSC-like Exosomes and Immuno-exosome's Repair Effectiveness of Damaged Skin Tissue.



Immuno-exosome

* Migrate rapidly to heal and regenerate the damaged skin.

Cell Migration Study – 2

	0 hr	24 hr
Control * Normal Skin Tissue		
Immuno-exosome * Damaged Skin Tissue Regeneration		
MSC Exosome * Damaged Skin Tissue Non-regeneration		

Immuno-exosome can be expected to improve skin wrinkles caused by aging by rapidly promoting differentiation and movement of skin cells, quickly regenerating damaged skin barriers and restoring reduced skin tissue density.

On the other hand, it is difficult to expect rapid skin regeneration and wrinkle improvement as the MSC-based exosomes promote differentiation and movement of skin cells.

Patents

Dynamic Linker Cells & Immuno-exosome Producing



Patent Number : 10-224304



Patent Number : 10-2285160

Toxicity Test Completion

Passed KFDA safety test

- 1) AUTE DERMAL DOSE TOXICITY TEST
- 2) 13 WEEKS DERMAL DOSE TOXICITY TEST
- 3) SKIN IRRITATION TEST
- 4) EYE IRRITATION TEST
- 5) SKIN SENSITIZATION TEST
- 6) PHOTOTOXICITY AND PHOTSENSITIZATION TEST
- 7) GENETIC TOXICITY TEST
- 8) PRIMARY SKIN IRRITATION TEST

Other tests

- 1) NO STEROID(39) TEST - OATC
- 2) NO PARABEN(7) AND ETHANOL TEST - TC
- 3) SKIN PATCH TEST FOR SENSITIVE SKIN - INNO - DERM

Certificate of Testing for Toxicity

BTJ Study No.: B19878
Final Report Amendment

QUALITY ASSURANCE STATEMENT (Final Report Amendment)

Study Title : Acute Dermal Dose Toxicity Study of Immunesco
in Sprague-Dawley Rats (Fixed Dose Procedure)
Study No. : B19878

This study was audited by the Quality Assurance Unit of Biotostech Co., Ltd. as indicated below. Audits were based on the GLPs, protocol and SOPs of Biotostech Co., Ltd. The result of quality assurance inspection and audit was reported to the study director and test facility management.

Audit phases and dates as described below were reported to the study director and test facility management.

Audit Phase	Audit Date	To Study Director and Test Facility Management
Final Report Amendment (1)	Dec. 17, 2021	Dec. 17, 2021

The amendment report was confirmed that the amendments were described suitably and guaranteed as consistency with the final report.

Biotostech Co., Ltd.
Quality Assurance Management Joong-Hwa Kim
Dec. 17, 2021

- 23 -

BTJ Study No.: B19879
Final Report Amendment

QUALITY ASSURANCE STATEMENT (Final Report Amendment)

Study Title : Thirteen-Week Repeated Dermal Dose Toxicity Study of Immunesco in
Sprague-Dawley Rat
Study No. : B19879

This study was audited by the Quality Assurance Unit of Biotostech Co., Ltd. as indicated below. Audits were based on the GLPs, protocol and SOPs of Biotostech Co., Ltd. The result of quality assurance inspection and audit was reported to the study director and test facility management.

Audit phases and dates as described below were reported to the study director and test facility management.

Audit Phase	Audit Date	To Study Director and Test Facility Management
Final Report Amendment (2)	Dec. 21, 2021	Dec. 21, 2021

The amendment report was confirmed that the amendments were described suitably and guaranteed as consistency with the final report.

Biotostech Co., Ltd.
Quality Assurance Management Joong-Hwa Kim
Dec. 21, 2021

- 23 -

BTJ Study No.: B19880
Final Report Amendment

QUALITY ASSURANCE STATEMENT (Final Report Amendment)

Study Title : Skin Sensitization test of Immunesco in CBA/J mice (Local lymph node
assay: IBDU-ELISA)
Study No. : B19880

This study was audited by the Quality Assurance Unit of Biotostech Co., Ltd. as indicated below. Audits were based on the GLPs, protocol and SOPs of Biotostech Co., Ltd. The result of quality assurance inspection and audit was reported to the study director and test facility management.

Audit phases and dates as described below were reported to the study director and test facility management.

Audit Phase	Audit Date	To Study Director and Test Facility Management
Final Report Amendment (2)	Dec. 17, 2021	Dec. 17, 2021

The amendment report was confirmed that the amendments were described suitably and guaranteed as consistency with the final report.

Biotostech Co., Ltd.
Quality Assurance Management Joong-Hwa Kim
Dec. 17, 2021

- 23 -

BTJ Study No.: B19882
Final Report Amendment

QUALITY ASSURANCE STATEMENT (Final Report Amendment)

Study Title : Photosensitization Study of Immunesco in Hartley Guinea Pigs
(Adjuvant & Strip Test)
Study No. : B19882

This study was audited by the Quality Assurance Unit of Biotostech Co., Ltd. as indicated below. Audits were based on the GLPs, protocol and SOPs of Biotostech Co., Ltd. The result of quality assurance inspection and audit was reported to the study director and test facility management.

Audit phases and dates as described below were reported to the study director and test facility management.

Audit Phase	Audit Date	To Study Director and Test Facility Management
Final Report Amendment (2)	Dec. 21, 2021	Dec. 21, 2021

The amendment report was confirmed that the amendments were described suitably and guaranteed as consistency with the final report.

Biotostech Co., Ltd.
Quality Assurance Management Joong-Hwa Kim
Dec. 21, 2021

- 23 -




Formula 2

PDRN

What is PDRN (Poly Deoxy Ribo Nucleotide) of EL EXOSOME?

It is a DNA obtained by extracting from the testicles of salmonidae fish and a regenerative activity material existing within the living body. This acts on tissue formation and cell division as a regenerative ingredient and helps to improve the skin within short-term period.



- ✓ Boosting proliferation of multiple growth factors
- ✓ Rapid regeneration of wounded skin
- ✓ Solving general skin problems with the activation of micro circulation


Benefits of PDRN

PDRN, DNA unit that is a basic unit for supplying energy to the human body, with a hyaluronic acid (natural moisturizing factor) is the strongest skin moisturizing and regeneration facilitating solution that can simultaneously stimulate the regeneration and shiny skin.




What is Niacinamide of EL EXOSOME?

'Niacinamide' is a typical whitening ingredient authorized its whitening and moisturizing effects by MFDS (Ministry of Food and Drug Safety)




Most people use cosmetics when they have dry skin. But it is not so effective. So, for the dry and elasticity losing skin, delivering Hyaluronic Acid directly to percutaneous layer of the skin is the most effective way to feel the immediate effect.

If you use a Delivery Injector exclusively for EL EXOSOME, you can expect even better effect.



When applying the cosmetics

it penetrates evenly to outer layer of skin





When applying the solution

it penetrates evenly to percutaneous layer of skin

Proven Results

Self-clinical test results

* Result may vary by different individual.

	1 week * Flushing	2 weeks * Improve complexion	3 weeks * Improve pores	4 weeks * Trouble relief
Before				
After				





Contact Us

Company | KL Global co.,Ltd

Inquiry | Tel : +82-2-3437-8106
E-mail : inquiry@klglobal.co.kr

Homepage | <http://www.klglobal.co.kr>
<http://www.medikmall.co.kr> (Official shop)

Location | Head office in Korea : 703-705 Ace High-End Seongsu Tower 14, Seongsui-ro 10-gil, Seongdong-gu, Seoul

China Branch : Xinyang Industrial Park 2-3, No. 330 Xinyang Road, Xiaozhaizi Community, Chengyang District, Qingdao City, Shandong Province (山东省青岛市城阳区小寨子社区兴阳路330号兴阳产业园2-3号房屋)

U.S.A Branch : BSG Aesthetics
5105 East Los Angeles Ave. Ste E, Simi Valley, CA 93063



**We develop together
with our partners**



K.L Global
Medical Beauty Solution

* It is a promotional material produced by KL Global Co., Ltd.
Unauthorized reproduction, theft, and redistribution of design or content are prohibited